Clinical Trial Update: SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial [Phase 1, Phase 2]

View source ↗

Summary

Clinical STOPTRAFFIC-1 trial evaluates SX-682 in combination with Nivolumab for RAS-mutated, MSS unresectable or metastatic colorectal cancer in Phase 1/2; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer
• Rectal Cancer
• Unresectable Colorectal Cancer

Drugs mentioned

• SX-682
• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING